CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 335 enrolled
Drug / intervention
Canagliflozin +3 moredrug
Likely dose
Canagliflozin 300 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02243202
NCT02243202Phase 2Completed
CompareCT.gov

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Safety and Efficacy of the Co-administration of Canagliflozin 300 mg and Phentermine 15 mg Compared With Placebo for the Treatment of Non-diabetic Overweight and Obese Subjects

Janssen Research & Development, LLC·interventional·Posted Sep 17, 2014·Updated Oct 6, 2016

In Brief

A Phase 2 clinical trial evaluating Canagliflozin, Phentermine, and 2 other interventions for Obesity. Completed, enrolled 335 participants across 17 sites.

Detailed Summary

The purpose of this study is to compare the effects of canagliflozin and phentermine to those of placebo to promote on a change in body weight over a 26 week period.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObesity
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedSep 17, 2014
Enrollment StartSep 1, 2014
Primary CompletionJun 1, 2015
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 11.8 years ago

Interventions

Canagliflozindrug

300 mg capsule, taken once daily, orally for 26 weeks.

Phenterminedrug

15 mg capsule, taken once daily, orally for 26 weeks.

Matching Placebo to Canagliflozindrug

Placebo capsules look like canagliflozin but do not contain any active drug, taken once daily, orally for 26 weeks.

Matching Placebo to Phenterminedrug

Placebo capsules look like phentermine but do not contain any active drug, taken once daily, orally for 26 weeks.